Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 76

Results For "PAT"

6779 News Found

Ascentage Pharma and Tanner Pharma Group initiate a global innovative named Patient Program
News | July 27, 2022

Ascentage Pharma and Tanner Pharma Group initiate a global innovative named Patient Program

Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.


Aarti Drugs reports consolidated Q1 FY23 PAT at Rs. 34.78 Cr
News | July 27, 2022

Aarti Drugs reports consolidated Q1 FY23 PAT at Rs. 34.78 Cr

Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.


Astec LifeSciences Q1 FY2023 consolidated PAT drops to Rs. 11.39 Cr
News | July 26, 2022

Astec LifeSciences Q1 FY2023 consolidated PAT drops to Rs. 11.39 Cr

The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.


Vikas Lifecare consolidated Q1FY23 PAT at Rs. 2.59 Cr
News | July 26, 2022

Vikas Lifecare consolidated Q1FY23 PAT at Rs. 2.59 Cr

The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.


GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr
News | July 26, 2022

GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr

GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022


Sanofi India Q2 CY2022 PAT drops 49.5% to Rs. 120.4 Cr
News | July 26, 2022

Sanofi India Q2 CY2022 PAT drops 49.5% to Rs. 120.4 Cr

Sanofi India has reported total income of Rs. 715 crores during the period ended June 30, 2022.


DS-7300 Phase 2 Trial Initiated in Patients with Pretreated ExtensiveStage Small Cell Lung Cancer
News | July 21, 2022

DS-7300 Phase 2 Trial Initiated in Patients with Pretreated ExtensiveStage Small Cell Lung Cancer

DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate


Roche launches Elecsys HCV Duo immunoassay for hepatitis C virus
News | July 20, 2022

Roche launches Elecsys HCV Duo immunoassay for hepatitis C virus

Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.


Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing
Clinical Trials | July 04, 2022

Clinical study of PD-L1 antibody ASC22 for cure of HIV completes first patient dosing

Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection


Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior
News | June 30, 2022

Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior

The settlement and dismissal resolves all claims between the parties